1/29
Comprehensive vocabulary flashcards covering endocrine physiology, diabetes pathophysiology, oral antidiabetics, insulin pharmacokinetics and administration, and thyroid disorders and pharmacology.

Endocrine Glands
Ductless glands that secrete hormones directly into the body to be transported by the bloodstream to specific target tissues.

Beta Cells
Endocrine cells located within the pancreatic islets that synthesize, store, and secrete insulin in response to glucose uptake and cellular depolarization.
Type 1 Diabetes
A condition characterized by autoimmune destruction of pancreatic beta cells leading to little or no endogenous insulin production; accounts for 10% of cases, typically has juvenile onset under age 20, and requires lifelong insulin injections.
Type 2 Diabetes
A metabolic disorder caused by multifactorial genetic defects and insulin resistance due to decreased or defective insulin receptors; accounts for 90% of cases and is strongly linked to obesity (80% of patients).
Normal Blood Glucose Levels (Without Diabetes)
Reference blood glucose parameters in non-diabetic individuals: fasting between 74 and 106 mg/dL, post-meal between 60 and 140 mg/dL, and an A1C between 4.0% and 6.0%.
Adult Diabetic Glycemic Goals
Target glycemic ranges in adults diagnosed with diabetes: fasting blood glucose of 70–120 mg/dL, post-meal glucose of 70–160 mg/dL, and an A1C of <7%.
Glinides
A subclass of insulin secretagogues (e.g., repaglinide, nateglinide) that stimulate pancreatic beta cells to release insulin for a short time; must be taken within 15–30 minutes before eating and withheld if a meal is skipped.
Sulfonylureas
A subclass of insulin secretagogues ending in the suffix -IDE (e.g., glyburide, glipizide, glimepiride) that stimulate the pancreas to release insulin continuously throughout the day; adverse effects include hypoglycemia, photosensitivity, fluid retention, and nephrotoxicity with renal impairment.
Biguanides
A class of insulin sensitizers (represented by metformin / Glucophage) that increase insulin receptor sensitivity to naturally secreted insulin and decrease hepatic glucose production; carries risks of lactic acidosis and GI distress, and does not cause hypoglycemia when used alone.
Metformin Renal Cutoffs and Contrast Protocol
Clinical nursing parameters requiring metformin to be withheld if serum creatinine exceeds 1.5 mg/dL in men or 1.4 mg/dL in women, and held for 48 hours following diagnostic studies using iodine contrast.
Incretin Mimetics (GLP-1 Agonists)
Injectable antidiabetic agents (e.g., exenatide, dulaglutide, semaglutide) that mimic natural gastrointestinal hormones to suppress glucagon release from the liver, delay gastric emptying, and promote satiety; associated with pancreatitis and thyroid C-cell tumors.
DPP-4 Inhibitors
Oral antidiabetics (e.g., sitagliptin / Januvia) that inhibit the enzyme dipeptidyl peptidase-4 to prevent the breakdown of incretin hormones; adverse effects include Stevens-Johnson syndrome, respiratory infections, and a high incidence of allergic reactions.
Sodium-Glucose Cotransport Inhibitors
Antidiabetic drugs (e.g., canagliflozin / Invokana) that prevent glucose reabsorption in the renal tubules, promoting urinary glucose excretion; adverse effects include dehydration, electrolyte imbalances, and pancreatitis.
Insulin (Cellular Action)
A pancreatic hormone that facilitates the active transport of glucose across cell membranes into target tissues and stimulates the conversion of glucose into stored glycogen.
Rapid-Acting Insulin
Insulin formulations including insulin lispro (Humalog) and insulin glulisine (Apidra) featuring an onset of 15 minutes, a peak of 1–2 hours, and an effective duration of 3–5 hours.
Short-Acting Insulin (Regular)
Clear insulin formulation (Humulin R) with an onset of 30 minutes to 1 hour, a peak effect at 2.5 hours, and a duration of action lasting 6–10 hours.
Intermediate-Acting Insulin (NPH)
Cloudy insulin formulation (Humulin N) with an onset of 1–2 hours, a peak between 4 and 8 hours, and a total duration of 10–18 hours.
Long-Acting Insulin (Glargine)
Basal insulin formulation (Lantus) with an onset of 1–2 hours, no peak, and a continuous duration of 24 hours.

Basal vs. Bolus Insulin Secretion
The physiological pattern of insulin release consisting of a continuous low-level baseline output (basal) combined with sharp secretory spikes triggered to handle mealtime glucose influx (bolus).
Hyperglycemia Symptoms
Clinical manifestations of excessively high blood glucose, including fruity breath odor, unsteady gait, dehydration, slurred speech, and the '3 P’s' (polyuria, polydipsia, and polyphagia).
Hypoglycemia Symptoms
Clinical manifestations of abnormally low blood glucose, including anxiety, confusion, tremors, weakness, intense hunger, diaphoresis, tachycardia, and pale, cool skin.
Injection Site Rotation
The systematic rotation of subcutaneous insulin injection sites across anatomical areas to ensure predictable drug absorption rates and prevent localized tissue lipodystrophy.

Clear Before Cloudy
The mandatory sequence for combining insulins in one syringe, where rapid- or short-acting regular insulin (clear) is drawn up first before intermediate-acting NPH insulin (cloudy) to prevent vial contamination.
Thyroid Gland Functions
The physiological roles of the thyroid gland, which include regulating basal metabolism, facilitating heat production, controlling core body temperature, and modulating cardiac output.
Hypothyroidism
A condition of thyroid hormone underproduction characterized clinically by fatigue, lethargy, bradycardia, obesity, hair loss, pale skin, cold intolerance, decreased body temperature, and goiter.
Hyperthyroidism
A condition of thyroid hyperfunction caused by Graves' disease, tumors, or excessive thyroid tissue growth; symptoms include fever, tachycardia, palpitations, flushing, heat intolerance, weight loss, goiter, and exophthalmus.

Exophthalmus
Abnormal forward protrusion or bulging of the eyes, characteristically seen in patients presenting with hyperthyroidism secondary to Graves' disease.

Goiter
An abnormal physical enlargement of the thyroid gland observable at the base of the neck, occurring in both hypothyroid and hyperthyroid disorders.
Propylthiouracil (PTU / Tapazole)
An antithyroid drug indicated for hyperthyroidism that inhibits the enzyme coupling iodine to tyrosine during T3 and T4 synthesis; major adverse effects include rash, headache, nausea, hepatotoxicity, and bone marrow suppression.
Levothyroxine (Synthroid)
A synthetic thyroid replacement hormone that increases cellular metabolic rate, cardiovascular activity, oxygen consumption, and cellular growth; adverse effects include insomnia, restlessness, seizures, chest pain, and myocardial infarction.